Evidence map›Paper›PMID 41479639›Full record

ReviewWorld journal of gastroenterology2025

Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models.

Jing-Ran Sun, Xiao-Ning Sun, Bing-Jiu Lu, Bao-Cheng Deng

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jing-Ran SunThe Second Department of Infectious Diseases, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China.
Xiao-Ning SunDepartment of Geriatrics, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China.
Bing-Jiu LuDepartment of Hepatology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China.
Bao-Cheng DengThe Second Department of Infectious Diseases, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China. sydengbc@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) is rapidly transforming the landscape of hepatology by enabling automated data interpretation, early disease detection, and individualized treatment strategies. Chronic liver diseases, including non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma, often progress silently and pose diagnostic challenges due to reliance on invasive biopsies and operator-dependent imaging. This review explores the integration of AI across key domains such as big data analytics, deep learning-based image analysis, histopathological interpretation, biomarker discovery, and clinical prediction modeling. AI algorithms have demonstrated high accuracy in liver fibrosis staging, hepatocellular carcinoma detection, and non-alcoholic fatty liver disease risk stratification, while also enhancing survival prediction and treatment response assessment. For instance, convolutional neural networks trained on portal venous-phase computed tomography have achieved area under the curves up to 0.92 for significant fibrosis (F2-F4) and 0.89 for advanced fibrosis, with magnetic resonance imaging-based models reporting comparable performance. Advanced methodologies such as federated learning preserve patient privacy during cross-center model training, and explainable AI techniques promote transparency and clinician trust. Despite these advancements, clinical adoption remains limited by challenges including data heterogeneity, algorithmic bias, regulatory uncertainty, and lack of real-time integration into electronic health records. Looking forward, the convergence of multi-omics, imaging, and clinical data through interpretable and validated AI frameworks holds great promise for precision liver care. Continued efforts in model standardization, ethical oversight, and clinician-centered deployment will be essential to realize the full potential of AI in hepatopathy diagnosis and treatment.

Indexed as

Artificial IntelligenceDeep LearningLiver DiseasesBig DataBiomarkersCarcinoma, HepatocellularData AnalyticsGastroenterologyHumansLiverLiver CirrhosisLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseBiomarkersArtificial intelligenceClinical prediction modelsDeep learningHepatologyLiver disease diagnosis

Identifiers

PMID41479639
PMCPMC12754151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.